A5079843897- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- MicroRNA in disease regulation
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Cancer-related molecular mechanisms research
- Reproductive System and Pregnancy
- Ectopic Pregnancy Diagnosis and Management
- Immune Cell Function and Interaction
- Neuroendocrine Tumor Research Advances
- Transplantation: Methods and Outcomes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Colorectal Cancer Treatments and Studies
- Bladder and Urothelial Cancer Treatments
- Inflammatory Bowel Disease
- Circular RNAs in diseases
- Cancer, Lipids, and Metabolism
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Machine Learning in Bioinformatics
- Endometriosis Research and Treatment
Norwegian University of Science and Technology
2008-2024
Levanger Hospital
2019-2024
The University of Melbourne
2022
Nordland Hospital Trust
2022
The Alfred Hospital
2012
Monash University
2012
University of California, Riverside
1988
Abstract Background Matching treatment based on tumour molecular characteristics has revolutionized the of some cancers and given hope to many patients. Although personalized cancer care is an old concept, renewed attention arisen due recent advancements in diagnostics including access high-throughput sequencing tissue. Targeted therapies interfering with specific pathways have been developed approved for subgroups These drugs might just as well be efficient other diagnostic subgroups, not...
Background: Improving the method for selecting participants lung cancer (LC) screening is an urgent need.Here we compare performance of HUNT Lung Cancer Model (HUNT LCM) versus NELSON and 2021 USPSTF criteria regarding LC risk prediction efficiency.Methods: We used linked data from ten Norwegian prospective population-based cohorts, Cohort Norway (CONOR).The study included 44,831 ever-smokers where 686 (1.5%) subjects developed LC, median follow-up time was 11.6 years (0.01-20.8...
Hypothesis We hypothesise that the validated HUNT Lung Cancer Risk Model would perform better than NLST (USA) and NELSON (Dutch‐Belgian) criteria in Danish Screening Trial (DLCST). Methods The DLCST measured only five out of seven variables included Model. Therefore a ‘Reduced’ model was retrained Norwegian HUNT2-cohort using same statistical methodology as original but based on age, pack years, smoking intensity, quit time body mass index (BMI), adjusted for sex. applied DLCST-cohort...
Small cell carcinoma of the urinary bladder is a rare subtype (incidence 1–9/1,000,000), characterized by an aggressive behavior with early metastasis and poor prognosis. Chemotherapy, radiation, surgery are usual treatment options, but to date, no accepted standard exists. Since small cancer shares similar clinicopathological features lung cancer, same type chemotherapy has been used. Recently, immune checkpoint inhibitors have shown effect in data regarding insufficient. Here we present...
8041 Background: With lung cancer incidence and mortality on the rise, blood biomarkers are increasingly in demand for early detection. The aim of this study is to discover validate novel based next-generation sequencing performed samples from non-cancer, ever-smokers up eight years prior diagnosis. Methods: Initial consideration was given serum population-based prospective HUNT2 HUNT3 cohorts, age > 18 (n = 98,737). Inclusion criteria cases were ever-smokers, no at entry, 0–8 between...
e20066 Background: As lung cancer incidence and mortality increase, methods of early diagnosis are needed to increase survival. The validated HUNT Lung Cancer Model (HUNT LCM) predicts individual 6-year risk in ever smokers with an AUC 0.87 based on eight clinical variables: sex, age, BMI, pack-years, smoking intensity number cigarettes per day, quit time, daily cough, indoors smoke exposure. We aimed explore whether the performance model can be improved by adding genetic information, what...
Abstract Introduction Blood biomarkers for early detection of lung cancer (LC) are in demand. There few studies the full microRNome serum asymptomatic subjects that later develop LC. Here we searched novel microRNA blood from non-cancer, ever-smokers populations up to eight years before diagnosis. Methods Serum samples 98,737 two prospective population studies, HUNT2 and HUNT3, were considered initially. Inclusion criteria cases were: ever-smokers; no known at study entrance; 0–8 sampling LC...
Abstract Purpose The HUNT Lung Cancer Model (HUNT LCM) predicts individualized 6-year lung cancer (LC) risk among individuals who ever smoked cigarettes with high precision based on eight clinical variables. Can the performance be improved by adding genetic information? Methods A polygenic model was developed in prospective Norwegian HUNT2 study and genotype data of ( n = 30749, median follow up 15.26 years) where 160 LC were diagnosed within six years. It included variables original LCM...
Abstract Background The characteristics of SARS-CoV-2 vaccine-induced immunity in inflammatory bowel disease (IBD) patients on immune modifying agents has not been clearly defined due to their exclusion vaccine trials. Emerging results suggest infliximab impairs antibody response compared vedolizumab. However there direct comparison controls. We evaluated this with both humoral and T cell IBD patients. Methods Antibody were analysed who received BNT162b2 (Pfizer–BioNTech) or ChAdOx1 nCoV-19...
e20696 Background: A novel validated model for risk prediction of lung cancer, the HUNT Lung Cancer Model predicts 6- and 16-year cancer with a C-index = 0.879 6-year AUC 0.87. The is valid smokers ex-smokers any intensity quit time includes seven variables; age, BMI, pack-years, smoking (cigarettes per day), time, daily cough in periods year hours indoors smoke exposure. Genome-wide association studies (GWAS) have consistently identified specific susceptibility regions. We aimed to improve...
Abstract Background: Matching treatment based on tumour molecular characteristics has revolutionized the of some cancers and given hope to many patients. Although personalized cancer care is an old concept, renewed attention arisen due recent advancements in diagnostics including access high-throughput sequencing tissue. Targeted therapies interfering with specific pathways have been developed approved for subgroups These drugs might just as well be efficient other diagnostic subgroups, not...
e16581 Background: Bladder cancer is the 6th most common in men and 17th women mortality high when detected advanced stage. Previous or current cigarette smoke main risk factor. There no screening program for bladder cancer. Given pathophysiological similarity with lung cancer, we postulated that a model could work The validated HUNT Lung Cancer Risk Model (HUNT LCM) predicts 6 years an area under ROC curve (AUC) of 0.87. Here aimed to test performance LCM prospective HUNT2 cohort 6-year...
e20095 Background: The high incidence and mortality rate of small-cell lung cancer (SCLC) calls for identification methods early diagnosis. Searching cancer-related proteins signature in biofluids is an emerging approach diagnostic malignancies. In the present study we have used proteomics-based profiling serum collected 2 months to 5 years before SCLC diagnosis search biomarkers. Methods: All samples this were obtained from Nord-Trøndelag Health Study (HUNT) Research Centre’s Biobank....